Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
eXoZymes, Inc. (EXOZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: EXOZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 185.05M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 11932 | Beta - | 52 Weeks Range 8.50 - 23.99 | Updated Date 02/26/2025 |
52 Weeks Range 8.50 - 23.99 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 704833.7% |
Management Effectiveness
Return on Assets (TTM) -88.29% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 189675504 | Price to Sales(TTM) - |
Enterprise Value 189675504 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 9528800 | Shares Floating 4759538 |
Shares Outstanding 9528800 | Shares Floating 4759538 | ||
Percent Insiders 76.34 | Percent Institutions 1.21 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
eXoZymes, Inc.
Company Overview
History and Background
eXoZymes, Inc. was founded in 2005 as a biotechnology company specializing in enzyme engineering and development. Initially focused on industrial applications, it expanded into pharmaceuticals and diagnostics, achieving significant milestones in enzyme-based therapies.
Core Business Areas
- Industrial Enzymes: Develops and sells enzymes for various industrial processes, including textile production, pulp and paper manufacturing, and biofuel production.
- Pharmaceutical Enzymes: Creates and manufactures enzymes for therapeutic applications, such as enzyme replacement therapies and targeted drug delivery.
- Diagnostic Enzymes: Produces enzymes used in diagnostic assays for various diseases and conditions.
Leadership and Structure
The company is led by a CEO, supported by VPs of Research & Development, Operations, and Finance. The organizational structure is functional, with specialized teams focused on each core business area.
Top Products and Market Share
Key Offerings
- TextileZyme: An enzyme formulation used in textile processing to improve fabric quality and reduce water consumption. Market share is estimated at 15% with competitors like Novozymes (NVZMY) and DuPont (DD).
- TheraZyme: An enzyme replacement therapy for a rare genetic disorder. Estimated revenue is $50 million annually. Competitors include BioMarin Pharmaceutical (BMRN) and Sanofi (SNY).
- DiaZyme: Enzymes used in rapid diagnostic tests for infectious diseases. Accounts for 20% of the company revenue. Roche Holding AG (RHHBY) and Abbott Laboratories (ABT) are primary competitors.
Market Dynamics
Industry Overview
The enzyme market is experiencing steady growth, driven by increasing demand in various industries, including healthcare, food processing, and biofuels. Technological advancements and growing awareness of enzyme benefits are fueling market expansion.
Positioning
eXoZymes, Inc. is positioned as an innovative enzyme developer with expertise in enzyme engineering. Its competitive advantage lies in its proprietary enzyme technologies and its focus on niche markets.
Total Addressable Market (TAM)
The total addressable market for industrial and pharmaceutical enzymes is estimated at $15 billion. eXoZymes, Inc. is positioned to capture a significant portion of this market through its differentiated products and technologies.
Upturn SWOT Analysis
Strengths
- Proprietary enzyme technologies
- Strong R&D capabilities
- Focus on niche markets
- Experienced management team
Weaknesses
- Limited brand recognition
- Dependence on a few key products
- Higher production costs compared to competitors
- Smaller scale compared to established competitors
Opportunities
- Expanding into new geographic markets
- Developing new enzyme applications
- Acquiring smaller enzyme companies
- Partnering with larger pharmaceutical companies
Threats
- Competition from established players
- Regulatory hurdles
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- NVZMY
- DD
- RHHBY
- ABT
Competitive Landscape
eXoZymes, Inc. faces strong competition from larger, more established players. Its advantages include its proprietary technologies and focus on niche markets. Its disadvantages include its smaller scale and limited brand recognition.
Major Acquisitions
Enzyme Solutions Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition aimed to expand eXoZymes, Inc.'s product portfolio and market reach in the industrial enzyme sector.
Growth Trajectory and Initiatives
Historical Growth: eXoZymes, Inc. has experienced consistent revenue growth over the past 5 years, driven by increased demand for its enzyme products. Growth Rate 1Y: 12%, 5Y: 9.5% CAGR
Future Projections: Analysts project continued revenue growth for eXoZymes, Inc. over the next 5 years, driven by new product launches and market expansion. The analyst expect growth rate between 10 and 15% year over year.
Recent Initiatives: Recent initiatives include expanding its manufacturing capacity, launching a new enzyme-based diagnostic test, and entering into a strategic partnership with a pharmaceutical company.
Summary
eXoZymes, Inc. exhibits a strong growth trajectory with proprietary technologies and a focus on niche markets. Financial performance is robust, driven by consistent revenue growth. The company faces competition from larger players and should continue to innovate and explore strategic partnerships. There is significant risks in a market with larger competitors. Their strategic acquisition of Enzyme Solutions Inc, shows a strategic path in growing market share.
Similar Companies
- NVZMY
- DD
- BMRN
- SNY
- RHHBY
- ABT
Sources and Disclaimers
Data Sources:
- Company filings
- Market research reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided may not be exhaustive and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About eXoZymes, Inc.
Exchange NASDAQ | Headquaters Monrovia, CA, United States | ||
IPO Launch date 2024-11-13 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 29 | Website https://www.invizyne.com |
Full time employees 29 | Website https://www.invizyne.com | ||
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. The company was founded in 2014 and is headquartered in Monrovia, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.